Astrazeneca PLC (AZN) stock had a bullish inflow of $3.91 million worth of trades on uptick and an outflow of $2.44 million in downticks on Tuesday. The total uptick to downtick ratio stood at 1.6. The net money flow into the stock was $1.47 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $1.41 million. $1.41 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Astrazeneca PLC (AZN) stock traded down $0.2 , and reached $33.1, a drop of -0.6% over the previous day. On a weekly basis, the stock is 0.15%, over the previous weeks close.
Also, Argus Research initiates coverage on Astrazeneca PLC (NYSE:AZN). The current rating of the shares is Hold, according to the research report released by the firm. The rating by the firm was issued on July 12, 2016.
AstraZeneca PLC has lost 1.83% in the last five trading days and dropped 0.55% in the last 4 weeks. AstraZeneca PLC is up 14.27% in the last 3-month period. Year-to-Date the stock performance stands at 2.33%.
Astrazeneca PLC (NYSE:AZN): The stock opened at $33.15 on Tuesday but the bulls could not build on the opening and the stock topped out at $33.31 for the day. The stock traded down to $33.07 during the day, due to lack of any buying support eventually closed down at $33.21 with a loss of -0.27% for the day. The stock had closed at $33.30 on the previous day. The total traded volume was 4,694,221 shares.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).